Lexaria Bioscience (LEXX) 10-Q 11 Apr 22 2022 Q2 Quarterly report Financial data

Cover

Cover - shares	6 Months Ended
	Feb. 28, 2022	Apr. 11, 2022
Cover [Abstract]
Entity Registrant Name	LEXARIA BIOSCIENCE CORP.
Entity Central Index Key	0001348362
Document Type	10-Q
Amendment Flag	false
Current Fiscal Year End Date	--02-28
Entity Small Business	true
Entity Shell Company	false
Entity Emerging Growth Company	false
Entity Current Reporting Status	Yes
Document Period End Date	Feb. 28, 2022
Entity Filer Category	Non-accelerated Filer
Document Fiscal Period Focus	Q2
Document Fiscal Year Focus	2022
Entity Common Stock Shares Outstanding		5,950,998
Document Quarterly Report	true
Document Transition Report	false
Entity Incorporation State Country Code	NV
Entity Tax Identification Number	20-2000871
Entity Interactive Data Current	Yes
Entity Address Address Line 1	#100 – 740 McCurdy Road
Entity Address City Or Town	Kelowna
Entity Address Postal Zip Code	V1X 2P7
City Area Code	1.250
Local Phone Number	765.6424
Entity Address Country	CA
Trading Symbol	LEXX
Security Exchange Name	NASDAQ
Entity Address State Or Province	BC
Security 12b Title	Common Stock, Par Value $0.001

CONSOLIDATED BALANCE SHEET

CONSOLIDATED BALANCE SHEET - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Current
Cash	$ 8,359,374	$ 10,917,797
Marketable securities	552,317	833,841
Accounts receivable	506,622	342,401
Inventory	31,927	29,648
Prepaid expenses and deposit	1,121,961	319,253
Total Current Assets	10,572,202	12,442,940
Non-current assets, net
Lease right of use	72,099	91,041
Intellectual property	411,452	364,623
Property & equipment	358,811	368,213
Total Non-current Assets	842,362	823,877
TOTAL ASSETS	11,414,564	13,266,817
Current
Accounts payable and accrued liabilities	116,592	100,723
Due to a related party	0	5,223
Loan payable	7,875	7,926
Lease payable	41,076	39,404
Total Current Liabilities	165,543	153,276
Long Term
Lease payable	29,080	49,989
Total Long Term Liabilities	29,080	49,989
TOTAL LIABILITIES	194,623	203,265
STOCKHOLDERS' EQUITY
Share Capital Authorized: 220,000,000 common voting shares with a par value of $0.001 per share Issued and outstanding: 5,950,998 common shares at February 28, 2022 and 5,726,699 common shares at August 31, 2021	5,951	5,727
Additional paid-in capital	46,697,434	45,089,114
Deficit	(35,248,137)	(31,829,204)
Equity attributable to shareholders of the Company	11,455,248	13,265,637
Non-controlling Interest	(235,307)	(202,085)
Total Stockholders' Equity	11,219,941	13,063,552
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	$ 11,414,564	$ 13,266,817

CONSOLIDATED BALANCE SHEET (Par

CONSOLIDATED BALANCE SHEET (Parenthetical) - $ / shares	Feb. 28, 2022	Aug. 31, 2021
CONSOLIDATED BALANCE SHEET
Common stock, shares authorized	220,000,000	220,000,000
Common stock, par value per share (in dollars per share)	$ 0.001	$ 0.001
Common stock, shares, issued	5,950,998	5,726,699
Common stock, shares, outstanding	5,950,998	5,726,699

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS
Revenue	$ 30,650	$ 192,006	$ 44,530	$ 487,662
Cost of goods sold	6,387	30,570	11,957	95,048
Gross profit	24,263	161,436	32,573	392,614
Expenses
Research and development	275,686	176,398	734,395	368,659
General and administrative	1,197,250	1,089,552	2,750,333	1,841,590
Total operating expenses	1,472,936	1,265,950	3,484,728	2,210,249
Loss from operations	(1,448,673)	(1,104,514)	(3,452,155)	(1,817,635)
Gain on disposal of assets		1,522,704	0	1,522,704
Discontinued operations	0	(25,000)	0	(22,000)
Net and comprehensive income (loss) for the period	(1,448,673)	393,190	(3,452,155)	(316,931)
Net and comprehensive income (loss) attributable to:
Common shareholders	(1,425,776)	404,111	(3,418,933)	(291,917)
Non-controlling interest	$ (22,897)	$ (10,921)	$ (33,222)	$ (25,014)
Basic and diluted income (loss) per share
Continuing operations	$ (0.25)	$ 0.10	$ (0.59)	$ (0.08)
Discontinued operations	0	(0.01)	0	(0.01)
Basic and diluted income (loss) per share	$ (0.25)	$ 0.09	$ (0.59)	$ (0.09)
Weighted average number of common shares outstanding
- Basic and diluted	5,911,123	4,052,904	5,818,401	3,524,286

CONSOLIDATED STATEMENT OF CASH

CONSOLIDATED STATEMENT OF CASH FLOWS - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Cash flows used in operating activities
Net loss and comprehensive loss	$ (3,452,154)	$ (294,931)
Adjustments to reconcile net loss to net cash used in operating activities:
Stock based compensation	408,544	66,041
Depreciation and amortization	54,093	55,859
Inventory write-off	0	2,482
Bad debt expense	0	37,000
Non-cash right of use lease expense	18,942	17,614
Gain on disposal of assets	0	(1,522,704)
Unrealized loss on marketable securities	(281,473)	(16,952)
Shares issued for services	300,000	0
Lease accretion	2,954	4,282
Change in working capital
Accounts receivable	164,221	69,264
Inventory	(1,161)	(16,883)
Prepaid expenses and deposits	97,292	(181,651)
Accounts payable and accrued liabilities	15,868	59,574
Due to related parties	(5,223)	148,102
Deferred revenue	0	43,255
Net cash used in by operating activities	(2,443,593)	(1,720,782)
Cash flows used in investing activities
Disposal (acquisition) of assets	(42,375)	273,375
Intellectual property	(50,263)	(8,766)
Net cash (used in) provided by investing activities	(92,638)	264,609
Cash flows from financing activities
Repayment of loan payable	0	(23,163)
Lease payments	(22,191)	(21,975)
Proceeds from issuance of equity	0	9,471,495
Net cash provided by (used in) financing Activities	22,191	9,426,357
Net cash provided by discontinued operations	0	83,000
Net change in cash for the period	(2,558,422)	8,053,184
Cash at beginning of period	10,917,797	1,293,749
Cash at end of period	8,359,374	9,346,933
Supplemental information of cash flows:
Income taxes paid in cash	0	3,450
Non-cash consideration on asset disposal	0	1,171,599
Non-cash shares for services included in prepaid expenses	$ 900,000	$ 0

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY - USD ($)	Total	Common Stock	Additional Paid-In Capital	Retained Earnings (Accumulated Deficit)	Noncontrolling Interest
Balance, shares at Aug. 31, 2020		3,001,476
Balance, amount at Aug. 31, 2020	$ 2,482,258	$ 3,001	$ 30,324,398	$ (27,802,198)	$ (42,943)
Stock based compensation	48,887	0	48,887	0	0
Net loss	(696,028)	0	0	(696,028)	0
Non-controlling interest	(14,093)	0	0	0	(14,093)
Balance, amount at Nov. 30, 2020	1,821,024	$ 3,001	30,373,285	(28,498,226)	(57,036)
Balance, shares at feb 28, 2022 at Nov. 30, 2020		3,001,476
Balance, shares at Aug. 31, 2020		3,001,476
Balance, amount at Aug. 31, 2020	2,482,258	$ 3,001	30,324,398	(27,802,198)	(42,943)
Net loss	(294,931)
Net Income	(22,000)
Shares issued for services, amount	0
Balance, amount at Feb. 28, 2021	11,702,865	$ 5,105	39,859,832	(28,094,115)	(67,957)
Balance, shares at feb 28, 2022 at Feb. 28, 2021		5,104,332
Balance, shares at Nov. 30, 2020		3,001,476
Balance, amount at Nov. 30, 2020	1,821,024	$ 3,001	30,373,285	(28,498,226)	(57,036)
Stock based compensation	17,154	0	17,154	0	0
Non-controlling interest	(10,921)	$ 0	0	0	(10,921)
Brokered placement, shares		2,102,856
Brokered placement, amount	9,471,497	$ 2,104	9,469,393	0	0
Net Income	404,111	0	0	404,111	0
Balance, amount at Feb. 28, 2021	11,702,865	$ 5,105	39,859,832	(28,094,115)	(67,957)
Balance, shares at feb 28, 2022 at Feb. 28, 2021		5,104,332
Stock based compensation	343,966	$ 0	343,966	0	0
Net loss	(2,556,997)	0	0	(2,556,997)	0
Non-controlling interest	(9,555)	0	0	0	(9,555)
Warrants issued for services	785,895	0	785,895	0	0
Balance, amount at May. 31, 2021	10,266,174	$ 5,105	40,989,693	(30,651,112)	(77,512)
Balance, shares at feb 28, 2022 at May. 31, 2021		5,104,332
Net loss	(1,178,092)	$ 0	0	(1,178,092)	0
Non-controlling interest	(124,573)	$ 0	0	0	(124,573)
Exercise of warrants, shares		610,189
Exercise of warrants, amount	4,015,043	$ 610	4,014,433	0	0
Shares issued for services, shares		12,178
Shares issued for services, amount	85,000	$ 12	84,988	0	0
Balance, amount at Aug. 31, 2021	13,063,552	$ 5,727	45,089,114	(31,829,204)	(202,085)
Balance, shares at feb 28, 2022 at Aug. 31, 2021		5,726,699
Stock based compensation	408,544	$ 0	408,544	0	0
Net loss	(1,993,157)	0	0	(1,993,157)	0
Non-controlling interest	(10,325)	0	0	0	(10,325)
Balance, amount at Nov. 30, 2021	11,468,614	$ 5,727	45,497,658	(33,822,361)	(212,410)
Balance, shares at feb 28, 2022 at Nov. 30, 2021		5,726,699
Balance, shares at Aug. 31, 2021		5,726,699
Balance, amount at Aug. 31, 2021	13,063,552	$ 5,727	45,089,114	(31,829,204)	(202,085)
Net loss	(3,452,154)
Net Income	0
Shares issued for services, amount	900,000
Balance, amount at Feb. 28, 2022	11,219,942	$ 5,951	46,697,434	(35,248,138)	(235,305)
Balance, shares at feb 28, 2022 at Feb. 28, 2022		5,950,998
Balance, shares at Nov. 30, 2021		5,726,699
Balance, amount at Nov. 30, 2021	11,468,614	$ 5,727	45,497,658	(33,822,361)	(212,410)
Net loss	(1,425,777)	0	0	(1,425,777)	0
Non-controlling interest	(22,895)	$ 0	0	0	(22,895)
Shares issued for services, shares		224,299
Shares issued for services, amount	1,200,000	$ 224	1,199,776	0	0
Balance, amount at Feb. 28, 2022	$ 11,219,942	$ 5,951	$ 46,697,434	$ (35,248,138)	$ (235,305)
Balance, shares at feb 28, 2022 at Feb. 28, 2022		5,950,998

Nature of Business

Nature of Business	6 Months Ended
	Feb. 28, 2022
Nature of Business
1. Nature of Business	1. Nature of Business Lexaria Bioscience Corp. (“Lexaria”, “we”, “our” or the “Company”) is a biotechnology company pursuing the enhancement of the bioavailability of a diverse and broad range of active pharmaceutical ingredients (“APIs”) using our patented drug delivery technology DehydraTECH TM Revenues are primarily derived from licensing fees for the use of the Company’s patented technology to partners who pay either a fee to use DehydraTECH in the manufacturing of their own products or through the purchase of DehydraTECH manufactured products made to their specifications by Lexaria. The Company has relationships with several consumer products companies in the CBD and nutraceuticals spaces that use Lexaria’s technology in consumer goods being sold online and at retailers in the US and Canada. The Company is headquartered in Kelowna, British Columbia, Canada. The corporate website is www.lexariabioscience.com Going Concern Analysis The Company’s consolidated financial statements included herein have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission (“SEC”) and in accordance with accounting principles generally accepted in the United States (“US GAAP”) applicable to a going concern which assumes the Company will have sufficient funds to pay it operational, research and development and capital expenditures for a period of at least 12 months from the date this financial report. Since inception, the Company has incurred significant operating and net losses. The losses attributable to common shareholders were $4.2m, $4.1m and $4.2m for the years ended August 31, 2021, 2020 and 2019, respectively. As of February 28, 2022, we had an accumulated deficit of $35.25m. We expect to continue to incur significant operational expenses and net losses in the upcoming 12 months. Our net losses may fluctuate significantly from quarter to quarter and year to year, depending on the stage and complexity of our R&D studies and related expenditures, the receipt of additional payments on the licencing of our technology, if any, and the receipt of payments under any current or future collaborations we may enter into. On January 12, 2021, the Company closed an underwritten public offering for net proceeds of $9,471,497. In the fourth quarter of the year ended August 31, 2021, the Company received $4,015,043 from the exercise of warrants. We may offer additional securities for sale during fiscal year 2022 or thereafter in response to market conditions or other circumstances if we believe such a plan of financing is required to advance the Company’s business plans and is in the best interests of our stockholders. The Company has evaluated whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Company’s ability to continue as a going concern. As of February 28, 2022, the Company had cash of approximately $8.4m. We believe this is sufficient to enable the Company to fund its operating and R&D expenses and any capital expenditure requirements through one year from the issuance date of these unaudited consolidated financial statements. To date, we have obtained cash and funded our operations primarily through equity financings and license agreements. In order to continue the development of our drug candidates, at some point in the future we expect to pursue one or more capital transactions, whether through the sale of equity securities, debt financing, license agreements or entry into strategic partnerships. There can be no assurance that we will be able to continue to raise additional capital in the future. COVID-19 Impacts of COVID-19 Pandemic The emergence of the COVID-19 pandemic in 2020 continues to present uncertainty and unforecastable new risks to the Company and its business plans. As of February 28, 2022, there has been no material impact on the Company’s financial position as a direct result of the pandemic. However, the Company has experienced some supply chain disruptions and shortages in the timely procurement of ingredients and supplies used in both our R&D activities and production. Management views this situation as transitory but cannot predict the length of time it may take for these disruptions to dissipate or if there will be a significant economic effect on the Company’s operations. In the interim, it may cause delays in carrying out our research studies and in our production schedules. Restrictions on international travel presents a challenge in carrying out normal business activities related to corporate finance efforts and the pursuit of new customers throughout North America who might otherwise access to our licensees’ retail products. As a result, the pandemic has increased the risk of lower revenues and higher losses. During the year ended August 31, 2020, we were in receipt of C$30,732 in COVID relief under the Canada Emergency Wage Subsidy programs for employees which reduced our employment costs in that year. During fiscal 2020 we also received C$40,000 from the Canadian Government sponsored Emergency Business Account loan program. As specified by the terms of this program, we have repaid C$30,000 of the loan in fiscal 2021. The remaining 7,875 (C$10,000) of the loan payable is anticipated to be forgiven as directed under this program in the year ended August 31, 2023. We continue to actively monitor the evolving effects of COVID-19 and may take further actions that alter our operations, including those that may be required by federal, state, provincial, or local authorities, or that we determine are in the best interests of our employees and third parties with which we do business. We do not know when it will become practical to relax or eliminate some or all these measures entirely. The economic effect of a prolonged pandemic is difficult to predict and could result in material financial impact in the Company’s future reporting periods.

Significant Accounting Policies

Significant Accounting Policies	6 Months Ended
	Feb. 28, 2022
Significant Accounting Policies
2. Significant Accounting Policies	2. Significant Accounting Policies The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2021.

Basis of Consolidation

Basis of Consolidation	6 Months Ended
	Feb. 28, 2022
Basis of Consolidation
3. Basis of Consolidation	3. Basis of Consolidation These interim consolidated financial statements include the financial statements of the Company and its wholly owned subsidiaries; Lexaria CanPharm ULC, Lexaria CanPharm Holdings Corp., PoViva Corp., Lexaria Hemp Corp., Kelowna Management Services Corp., and Lexaria Pharmaceutical Corp., and our 83.333% owned subsidiary Lexaria Nicotine LLC (16.667% Altria Ventures Inc., an indirect wholly owned subsidiary of Altria Group, Inc.). All significant intercompany balances and transactions have been eliminated upon consolidation.

Basis of Presentation

Basis of Presentation	6 Months Ended
	Feb. 28, 2022
Basis of Presentation
4. Basis of Presentation	4. Basis of Presentation The Company’s unaudited interim consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in annual financial statements prepared in accordance with United States generally accepted accounting principles (US GAAP) have been condensed or omitted pursuant to such rules and regulations. In the opinion of management, all adjustments considered necessary for a fair presentation have been included. Interim results are not necessarily indicative of results for a full year or any subsequent period. These unaudited interim consolidated financial statements should be read in conjunction with the audited consolidated annual financial statements and notes thereto included in our annual report filed on Form 10-K for the year ended August 31, 2021.

Estimates and Judgments

Estimates and Judgments	6 Months Ended
	Feb. 28, 2022
Estimates and Judgments
5. Estimates and Judgments	5. Estimates and Judgements The preparation of financial statements in conformity with U.S. GAAP requires us to make certain estimates, judgments and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent liabilities at the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Some of the Company’s accounting policies require us to make subjective judgments, often as a result of the need to make estimates of matters that are inherently uncertain. These accounting policies involve critical accounting estimates because they are particularly dependent on estimates and assumptions made by management about matters that are highly uncertain at the time the accounting estimates are made. Although we have used our best estimates based on facts and circumstances available to us at the time, different estimates reasonably could have been used. Changes in the accounting estimates used by the Company are reasonably likely to occur from time to time, which may have a material effect on the presentation of financial condition and results of operations. The Company reviews these estimates, judgments, and assumptions periodically and reflect the effects of revisions in the period in which they are deemed to be necessary. Although we believe that these estimates are reasonable actual results could differ. In preparing these unaudited interim consolidated financial statements, the significant judgments made by management in applying the Company’s accounting policies and the key sources of estimation uncertainty were the same as those applied to the audited consolidated financial statements for the year ended August 31, 2021.

Recent Accounting Guidance

Recent Accounting Guidance	6 Months Ended
	Feb. 28, 2022
Recent Accounting Guidance
6. Recent Accounting Guidance	6. Recent Accounting Guidance Pronouncements Issued but Not Yet Adopted In October of 2021, the FASB issued an update to Government Assistance (topic 832) to increase the transparency of government assistance and its disclosure in the notes to the financial statements. Amendments in this update take effect for annual periods beginning after December 31, 2021. Early application of the amendments is permitted. The Company does not expect the adoption of these standards to have a material impact on its consolidated financial statements In June 2016, the FASB issued ASU No. 2016-13, Financial Instruments—Credit Losses (Topic 326): Measurement of Credit Losses on Financial Instruments. The FASB subsequently issued amendments to ASU 2016-13, which have the same effective date and transition date of January 1, 2023. These standards require that credit losses be reported using an expected losses model rather than the incurred losses model that is currently used, and establishes additional disclosures related to credit risks. For available-for-sale debt securities with unrealized losses, these standards now require allowances to be recorded instead of reducing the amortized cost of the investment. These standards limit the amount of credit losses to be recognized for available-for-sale debt securities to the amount by which carrying value exceeds fair value and requires the reversal of previously recognized credit losses if fair value increases. The Company does not currently expect the adoption of these standards to have a material impact on its consolidated financial statements.

Accounts and Other Receivables

Accounts and Other Receivables	6 Months Ended
	Feb. 28, 2022
Accounts and Other Receivables
7. Accounts and Other Receivables	7. Accounts and Other Receivables February 28, August 31, 2022 2021 $ $ Trade and deposits receivable 19,016 16,553 Sale of assets - shares receivable 278,107 287,107 Sales tax receivable 209,499 47,741 506,622 342,401

Inventory

Inventory	6 Months Ended
	Feb. 28, 2022
Inventory
8. Inventory	8. Inventory February 28, August 31, 2022 2021 $ $ Raw materials 31,927 29,648 31,927 29,648 During the period ended February 28, 2022, the Company wrote down $Nil (February 28, 2021-$2,482) in finished goods.

Intellectual Property

Intellectual Property	6 Months Ended
	Feb. 28, 2022
Intellectual Property
9. Intellectual Property	9. Intellectual Property The following is a list of US capitalized patents held by the Company: Issued Patent # Patent Certificate Grant Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 US 10,756,180 08/25/2020 A continuity schedule for capitalized patents is presented below: February 28, 2022 August 31, 2021 $ $ Balance – beginning 364,623 292,000 Addition 50,263 79,493 Amortization (3,434 ) (6,870 ) Balance – ending 411,452 364,623 Patents are amortized over their 20 year legal life.

Property and Equipment

Property and Equipment	6 Months Ended
	Feb. 28, 2022
Property and Equipment
10. Property & Equipment	10. Property & Equipment Six Months Ended February 28, 2022 Cost Period Amortization Additions Accumulated Amortization Net Balance February 28, 2022 $ $ $ $ $ Leasehold improvements 259,981 (27,019 ) - (167,667 ) 92,314 Computers 63,964 (8,075 ) - (59,625 ) 4,339 Furniture fixtures & equipment 31,126 (3,209 ) - (19,629 ) 11,497 Lab equipment 291,235 13,474 ) 42,375 (82,949 ) 250,661 646,306 (51,777 ) 42,375 (329,870 ) 358,811 For the six months ended February 28, 2022, amortization of $1,118 (February 28, 2021 - $6,010) was included in the cost of goods sold. Year Ended August 31, 2021 Cost Period Amortization Disposal Accumulated Amortization Net Balance August 31, 2021 $ $ $ $ $ Leasehold improvements 259,981 (54,038 ) - (140,648 ) 119,333 Computers 63,964 (19,681 ) - (51,550 ) 12,414 Furniture fixtures & equipment 34,220 (6,417 ) (3,094 ) (16,420 ) 14,706 Lab equipment 291,235 (35,008 ) - (69,475 ) 221,760 649,400 (115,144 ) (3,094 ) (279,093 ) 368,213

Accounts Payable and Accrued Li

Accounts Payable and Accrued Liabilities	6 Months Ended
	Feb. 28, 2022
Accounts Payable and Accrued Liabilities
11. Accounts Payable and Accrued Liabilities	11. Accounts Payable and Accrued Liabilities February 28, August 31, 2022 2021 $ $ Accounts Payable Trades payable 60,873 54,668 Sales tax payable 33,244 - Accrued Liabilities Corporate tax payable - 1,055 Trades payable 22,474 45,000 Balance 116,591 100,723

Common Shares and Warrants

Common Shares and Warrants	6 Months Ended
	Feb. 28, 2022
Common Shares and Warrants
12. Common Shares and Warrants	12. Common Shares and Warrants In December of 2021, the Company entered a one-year media outreach agreement to SRAX Inc. and issued 224,299 shares as consideration for an aggregate value of $1.2m. During the quarter ended February 28, 2022, the Company issued no warrants. A continuity schedule for warrants is presented below: Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2020 471,608 16.77 Cancelled/expired (44,161 ) 67.50 Exercised (610,189 ) 6.58 Issued 2,630,017 6.58 Balance August 31, 2021 2,447,275 8.00 Cancelled/expired (25,292 ) 4.57 Balance February 28, 2022 2,421,983 8.04 A summary of warrants outstanding as of February 28, 2022, is presented below: # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 7,500 0.68 years 24.00 100,000 2.13 years 9.00 200,000 2.13 years 7.00 51,814 2.71 years 36.00 8,984 2.75 years 36.00 16,667 3.05 years 9.00 317,190 3.20 years 10.50 1,719,828 3.88 years 6.58 2,421,983 3.53 years 8.04

Stock Options

Stock Options	6 Months Ended
	Feb. 28, 2022
Stock Options
13. Stock Options	13. Stock Options The Company has established the Equity Incentive Plan whereby the board of directors may, from time to time, grant stock options up to the equivalent of 10% of the number of common shares issued and outstanding to directors, officers, employees, and consultants. Stock options granted must be exercised within five years from the date of grant or such lesser period as determined by the Company’s board of directors. The exercise price of an option is equal to or greater than the closing market price of the Company’s common shares on the day preceding the date of grant. The vesting terms of each grant are set by the board of directors. The Company did not grant any options during the quarter ended February 28, 2022. A continuity schedule for stock options is presented below: Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2020 171,604 11.17 Cancelled/expired (50,334 ) 10.76 Granted 84,900 5.41 Balance August 31, 2021 206,170 8.90 Cancelled (3,334 ) 9.60 Granted 81,800 6.23 Balance February 28, 2022 (Outstanding) 284,636 8.12 3.61 - Balance February 28, 2022 (Exercisable) 260,386 8.35 3.59 - The fair value of share purchase options granted were estimated as of the date of the grant by using the Black-Scholes option pricing model with the following assumptions: February 28, 2022 Expected volatility 119 % Risk-free interest rate 0.85 % Expected life 5 years Dividend yield 0 % Estimated fair value per option $ 5.10

Revenues

Revenues	6 Months Ended
	Feb. 28, 2022
Revenues
14. Revenues	14. Revenues February 28, 2022 $ February 28, 2021 $ Product sales 17,512 231,718 Licensing revenue 16,160 255,844 Other revenue 10,858 100 Income from operations 44,530 487,662 Product revenues of $17.5k and licensing usage fees of $16k represent a significant decrease in intermediate product sales and related licensing usage fees during the six months ended February 28, 2022.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Feb. 28, 2022
Related Party Transactions
15. Related Party Transactions	15. Related Party Transactions Due to related parties Related party transactions are recorded at the exchange amount established and agreed to between the related parties. As at February 28, 2022, $6,884, included in accrued liabilities. At August 31, 2021 - $5,223 was payable to and included in due to related parties.

Segment Information

Segment Information	6 Months Ended
	Feb. 28, 2022
Segment Information
16. Segment Information	16. Segment Information The Company’s operations involve the development and usage, including licensing, of its proprietary DehydraTECH Technology. Lexaria is centrally managed and its chief operating decision makers, being the President and the CEO, use the consolidated and other financial information supplemented by revenue information by category of alternative health consumer products and technology licensing to make operational decisions and to assess the performance of the Company. The Company has identified two reportable segments: Intellectual Property and Products. Licensing revenues are significantly concentrated on one licensee. Six Months Ended February 28, 2022 IP Licensing $ Products $ Corporate $ Consolidated Total $ Revenue 16,160 17,512 10,858 44,530 Cost of goods sold - (11,957 ) - (11,957 ) Operating expenses (1,367,712 ) (190,611 ) (1,926,406 ) (3,484,729 ) Segment loss (1,351,552 ) (185,056 ) (1,915,548 ) 3,452,156 ) Total assets 939,790 87,291 10,387,483 11,414,564 Six Months Ended February 28, 2021 IP Licensing $ Products $ Corporate $ Consolidated Total $ External revenue 255,844 231,818 - 487,662 Cost of goods sold - (95,048 ) - (95,048 ) Operating expenses 1,142,518 (278,374 ) (1,551,689 ) (687,545 ) Discontinued operations (22,000 ) - - (22,000 ) Segment income (loss) 1,376,362 (141,604 ) (1,551,689 ) (316,931 ) Total assets 696,493 137,282 11,338,633 12,172,408 Capital Asset by Region Cost US Addition US Net Balance US Cost Canada Net Balance Canada Total Net Balance Six Months Ended February 28, 2022 $ $ $ $ $ $ Leasehold Improvements - - - 259,981 92,314 92,314 Computers - - - 63,964 4,339 4,339 Furniture Fixtures Equipment - - - 31,126 11,497 11,497 Lab Equipment 98,050 42,375 108,144 193,185 142,517 250,661 98,050 42,375 108,144 548,256 250,667 358,811 Capital Asset by Region Cost US Disposal US Net Balance US Cost Canada Net Balance Canada Total Net Balance Year Ended August 31, 2021 $ $ $ $ $ $ Leasehold Improvements - - - 259,981 119,333 119,333 Computers - - - 63,964 12,414 12,414 Furniture Fixtures Equipment 3,094 (3,094 ) - 31,126 14,706 14,706 Lab Equipment 98,050 - 69,580 193,185 152,180 221,760 101,144 (3,094 ) 69,580 548,256 298,633 368,213

Commitments Significant Contrac

Commitments Significant Contracts and Contingencies	6 Months Ended
	Feb. 28, 2022
Commitments Significant Contracts and Contingencies
17. Commitments, Significant Contracts and Contingencies	17. Commitments, Significant Contracts and Contingencies Right of Use Assets - Operating Lease The Corporate office and R&D laboratory located in Kelowna, British Columbia, Canada is leased until November 15, 2023, with a five-year renewal option. In addition to minimum lease payments, the lease requires us to pay, subject to annual adjustments, property taxes and operating costs. February 28, 2022 August 31, 2021 $ $ Right of use assets - operating leases 126,920 126,920 Amortization (54,821 ) (35,879 ) Total lease assets 72,099 91,041 Liabilities: 89,393 125,431 Lease payments (22,191 ) (43,950 ) Interest accretion 2,954 7,912 Total lease liabilities 70,156 89,393 Operating lease cost 72,099 91,041 Operating cash flows for lease 22,191 43,950 Remaining lease term 1.7 Years 2.1 Years Discount rate 7.50 % 7.50 % Pursuant to the terms of the Company’s lease agreements in effect, the following table summarizes the Company’s maturities of operating lease liabilities as of February 28: 2022 $ 22,407 2023 44,816 2024 7,469 Thereafter - Total lease payments $ 74,692 Less: imputed interest (4,536 ) Present value of operating lease liabilities $ 70,156 Less: current obligations under leases (41,076 ) Total $ 29,080

Prepaid Expenses and Deposits

Prepaid Expenses and Deposits	6 Months Ended
	Feb. 28, 2022
Prepaid Expenses and Deposits
18. Prepaid Expenses and Deposits	18. Prepaid Expenses and Deposits Prepaid expenses consist of the following at February 28, 2022, and August 31, 2021: February 28, August 31, 2022 2021 $ $ Advertising & conferences 1,015,367 168,760 Consulting - 18,750 Legal fees 25,000 31,380 Licence, filing fees, dues 37,500 19,500 Office & insurance 44,094 80,863 1,121,961 319,253

Marketable Securities

Marketable Securities	6 Months Ended
	Feb. 28, 2022
Marketable Securities
19. Marketable Securities	19. Marketable Securities The components of Marketable Securities were as follows: Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2021 Common stock 1,037,025 16,243 (219,427 ) Total 1,037,025 16,243 (219,427 ) 833,841 February 28, 2022 Common stock - 58,893 340,417 ) (281,524 ) Total 1,037,025 73,156 (559,844 ) 552,317 Unrealized gains and losses from common stock are due to market price movements. Management does not believe any remaining unrealized losses represent other-than-temporary impairments based on our evaluation of available evidence.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Feb. 28, 2022
Discontinued Operations
20. Discontinued Operations	20. Discontinued Operations On November 19, 2020, the Company entered a definitive asset sale agreement through its wholly owned subsidiary Lexaria CanPharm ULC to sell certain non-core business assets to Hill Street Beverage Company (“Hill Street”) (TSX-V: BEER) for gross proceeds of C$3,850,000. With the closing of the sale on December 10, 2020, the Company received C$350,000 in cash, 6,031,363 restricted common shares at a fair value at C$500,000 as the first required equity-based payment, and a C$2,000,000 promissory note bearing interest at 10% per annum. The promissory note was included at its nominal value of $NIL. Pursuant to the terms of the transaction, the Company will receive an additional C$1,000,000 worth of common shares of Hill Street of which C$643,939 worth of Hill Street shares were issued to the Company on August 9, 2021, and the remaining C$356,061 worth of Hill Street shares are to be issued on April 9, 2022. Gain on asset disposal Book value of assets sold $ - Cash consideration 273,373 Shares received 468,264 Shares receivable 781,067 Promissory note - $ 1,522,704 The financial results of the group of assets sold are presented as income (loss) from discontinued operations, net of income taxes in our consolidated statement of income. The following table presents financial results of the assets: SIX MONTHS ENDED February 28, 2022 2021 Revenue $ - $ 3,000 Operating Expenses - 25,000 Net Income (loss) $ - $ (22,000 ) The following table presents cash flows of discontinued operations: SIX MONTHS ENDED February 28, 2022 2021 Cash flows used in discontinued operating activities Net income $ - $ (22,000 ) Change in working capital - 105,000 Net cash used in discontinued operating activities $ - $ 83,000 Net cash provided by discontinued operations - $ 83,000

Subsequent Events

Subsequent Events	6 Months Ended
	Feb. 28, 2022
Subsequent Events
21. Subsequent Events	21. Subsequent Events On March 8, 2022 Lexaria granted 36,700 stock options bearing an exercise price of $3.39 for a period of five years ending March 8, 2027. The Options were issued pursuant to the Company’s registered Incentive Equity Plan and any common shares issued upon the exercise of the Options will be unrestricted securities.

Significant Accounting Polici_2

Significant Accounting Policies (Policies)	6 Months Ended
	Feb. 28, 2022
Significant Accounting Policies
Basis of presentation	The significant accounting policies of the Company are consistent with those of our audited financial statements on Form 10-K for the year ended August 31, 2021.

Accounts and Other Receivables

Accounts and Other Receivables (Tables)	6 Months Ended
	Feb. 28, 2022
Accounts and Other Receivables
Tabular disclosure of accounts and other receivable.	February 28, August 31, 2022 2021 $ $ Trade and deposits receivable 19,016 16,553 Sale of assets - shares receivable 278,107 287,107 Sales tax receivable 209,499 47,741 506,622 342,401

Inventory (Tables)

Inventory (Tables)	6 Months Ended
	Feb. 28, 2022
Inventory
Schedule of Inventory	February 28, August 31, 2022 2021 $ $ Raw materials 31,927 29,648 31,927 29,648

Intellectual Property (Tables)

Intellectual Property (Tables)	6 Months Ended
	Feb. 28, 2022
Intellectual Property
Schedule of US capitalized patents	Issued Patent # Patent Certificate Grant Date Patent Family US 9,474,725 B1 10/25/2016 Food and Beverage Compositions Infused With Lipophilic Active Agents and Methods of Use Thereof US 9,839,612 B2 12/12/2017 US 9,972,680 B2 05/15/2018 US 9,974,739 B2 05/22/2018 US 10,084,044 B2 09/25/2018 US 10,103,225 B2 10/16/2018 US 10,381,440 08/13/2019 US 10,374,036 08/06/2019 US 10,756,180 08/25/2020
Schedule of patents	February 28, 2022 August 31, 2021 $ $ Balance – beginning 364,623 292,000 Addition 50,263 79,493 Amortization (3,434 ) (6,870 ) Balance – ending 411,452 364,623

Property Equipment (Tables)

Property Equipment (Tables)	6 Months Ended
	Feb. 28, 2022
Property and Equipment
Schedule of property & equipment	Six Months Ended February 28, 2022 Cost Period Amortization Additions Accumulated Amortization Net Balance February 28, 2022 $ $ $ $ $ Leasehold improvements 259,981 (27,019 ) - (167,667 ) 92,314 Computers 63,964 (8,075 ) - (59,625 ) 4,339 Furniture fixtures & equipment 31,126 (3,209 ) - (19,629 ) 11,497 Lab equipment 291,235 13,474 ) 42,375 (82,949 ) 250,661 646,306 (51,777 ) 42,375 (329,870 ) 358,811 For the six months ended February 28, 2022, amortization of $1,118 (February 28, 2021 - $6,010) was included in the cost of goods sold. Year Ended August 31, 2021 Cost Period Amortization Disposal Accumulated Amortization Net Balance August 31, 2021 $ $ $ $ $ Leasehold improvements 259,981 (54,038 ) - (140,648 ) 119,333 Computers 63,964 (19,681 ) - (51,550 ) 12,414 Furniture fixtures & equipment 34,220 (6,417 ) (3,094 ) (16,420 ) 14,706 Lab equipment 291,235 (35,008 ) - (69,475 ) 221,760 649,400 (115,144 ) (3,094 ) (279,093 ) 368,213

Accounts Payable and Accrued _2

Accounts Payable and Accrued Liabilities (Tables)	6 Months Ended
	Feb. 28, 2022
Accounts Payable and Accrued Liabilities
Schedule of accounts payable and accrued liabilities	February 28, August 31, 2022 2021 $ $ Accounts Payable Trades payable 60,873 54,668 Sales tax payable 33,244 - Accrued Liabilities Corporate tax payable - 1,055 Trades payable 22,474 45,000 Balance 116,591 100,723

Common Shares and Warrants (Tab

Common Shares and Warrants (Tables)	6 Months Ended
	Feb. 28, 2022
Common Shares and Warrants
Represents the tabular disclosure of share issuance relating to option and warrant exercises.	Number of Warrants Weighted Average Exercise Price $ Balance August 31, 2020 471,608 16.77 Cancelled/expired (44,161 ) 67.50 Exercised (610,189 ) 6.58 Issued 2,630,017 6.58 Balance August 31, 2021 2,447,275 8.00 Cancelled/expired (25,292 ) 4.57 Balance February 28, 2022 2,421,983 8.04 # of Warrants Weighted Average Remaining Contractual Life Weighted Average Exercise Price $ 7,500 0.68 years 24.00 100,000 2.13 years 9.00 200,000 2.13 years 7.00 51,814 2.71 years 36.00 8,984 2.75 years 36.00 16,667 3.05 years 9.00 317,190 3.20 years 10.50 1,719,828 3.88 years 6.58 2,421,983 3.53 years 8.04

Stock Options (Tables)

Stock Options (Tables)	6 Months Ended
	Feb. 28, 2022
Stock Options
Schedule of exercise price	Options Weighted Average Exercise Price $ Weighted Average Remaining Contractual Term (Years) Aggregate Intrinsic Value $ Balance August 31, 2020 171,604 11.17 Cancelled/expired (50,334 ) 10.76 Granted 84,900 5.41 Balance August 31, 2021 206,170 8.90 Cancelled (3,334 ) 9.60 Granted 81,800 6.23 Balance February 28, 2022 (Outstanding) 284,636 8.12 3.61 - Balance February 28, 2022 (Exercisable) 260,386 8.35 3.59 - February 28, 2022 Expected volatility 119 % Risk-free interest rate 0.85 % Expected life 5 years Dividend yield 0 % Estimated fair value per option $ 5.10

Revenues (Tables)

Revenues (Tables)	6 Months Ended
	Feb. 28, 2022
Revenues
Schedule of revenue	February 28, 2022 $ February 28, 2021 $ Product sales 17,512 231,718 Licensing revenue 16,160 255,844 Other revenue 10,858 100 Income from operations 44,530 487,662

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Feb. 28, 2022
Segment Information
Schedule of the profit or loss and total assets for each reportable segment	Six Months Ended February 28, 2022 IP Licensing $ Products $ Corporate $ Consolidated Total $ Revenue 16,160 17,512 10,858 44,530 Cost of goods sold - (11,957 ) - (11,957 ) Operating expenses (1,367,712 ) (190,611 ) (1,926,406 ) (3,484,729 ) Segment loss (1,351,552 ) (185,056 ) (1,915,548 ) 3,452,156 ) Total assets 939,790 87,291 10,387,483 11,414,564 Six Months Ended February 28, 2021 IP Licensing $ Products $ Corporate $ Consolidated Total $ External revenue 255,844 231,818 - 487,662 Cost of goods sold - (95,048 ) - (95,048 ) Operating expenses 1,142,518 (278,374 ) (1,551,689 ) (687,545 ) Discontinued operations (22,000 ) - - (22,000 ) Segment income (loss) 1,376,362 (141,604 ) (1,551,689 ) (316,931 ) Total assets 696,493 137,282 11,338,633 12,172,408 Capital Asset by Region Cost US Addition US Net Balance US Cost Canada Net Balance Canada Total Net Balance Six Months Ended February 28, 2022 $ $ $ $ $ $ Leasehold Improvements - - - 259,981 92,314 92,314 Computers - - - 63,964 4,339 4,339 Furniture Fixtures Equipment - - - 31,126 11,497 11,497 Lab Equipment 98,050 42,375 108,144 193,185 142,517 250,661 98,050 42,375 108,144 548,256 250,667 358,811 Capital Asset by Region Cost US Disposal US Net Balance US Cost Canada Net Balance Canada Total Net Balance Year Ended August 31, 2021 $ $ $ $ $ $ Leasehold Improvements - - - 259,981 119,333 119,333 Computers - - - 63,964 12,414 12,414 Furniture Fixtures Equipment 3,094 (3,094 ) - 31,126 14,706 14,706 Lab Equipment 98,050 - 69,580 193,185 152,180 221,760 101,144 (3,094 ) 69,580 548,256 298,633 368,213

Commitments Significant Contr_2

Commitments Significant Contracts and Contingencies (Tables)	6 Months Ended
	Feb. 28, 2022
Commitments Significant Contracts and Contingencies
Schedule of management and service agreements	February 28, 2022 August 31, 2021 $ $ Right of use assets - operating leases 126,920 126,920 Amortization (54,821 ) (35,879 ) Total lease assets 72,099 91,041 Liabilities: 89,393 125,431 Lease payments (22,191 ) (43,950 ) Interest accretion 2,954 7,912 Total lease liabilities 70,156 89,393 Operating lease cost 72,099 91,041 Operating cash flows for lease 22,191 43,950 Remaining lease term 1.7 Years 2.1 Years Discount rate 7.50 % 7.50 % 2022 $ 22,407 2023 44,816 2024 7,469 Thereafter - Total lease payments $ 74,692 Less: imputed interest (4,536 ) Present value of operating lease liabilities $ 70,156 Less: current obligations under leases (41,076 ) Total $ 29,080

Prepaid Expenses (Tables)

Prepaid Expenses (Tables)	6 Months Ended
	Feb. 28, 2022
Prepaid Expenses and Deposits
Schedule of Prepaid Expenses	February 28, August 31, 2022 2021 $ $ Advertising & conferences 1,015,367 168,760 Consulting - 18,750 Legal fees 25,000 31,380 Licence, filing fees, dues 37,500 19,500 Office & insurance 44,094 80,863 1,121,961 319,253

Marketable Securities (Tables)

Marketable Securities (Tables)	6 Months Ended
	Feb. 28, 2022
Marketable Securities
Schedule of marketable securities	Cost Basis $ Unrealized Gains $ Unrealized Losses $ Total $ August 31, 2021 Common stock 1,037,025 16,243 (219,427 ) Total 1,037,025 16,243 (219,427 ) 833,841 February 28, 2022 Common stock - 58,893 340,417 ) (281,524 ) Total 1,037,025 73,156 (559,844 ) 552,317

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Feb. 28, 2022
Discontinued Operations
Schedule on gain on asset disposal	Gain on asset disposal Book value of assets sold $ - Cash consideration 273,373 Shares received 468,264 Shares receivable 781,067 Promissory note - $ 1,522,704 SIX MONTHS ENDED February 28, 2022 2021 Revenue $ - $ 3,000 Operating Expenses - 25,000 Net Income (loss) $ - $ (22,000 ) SIX MONTHS ENDED February 28, 2022 2021 Cash flows used in discontinued operating activities Net income $ - $ (22,000 ) Change in working capital - 105,000 Net cash used in discontinued operating activities $ - $ 83,000 Net cash provided by discontinued operations - $ 83,000

Nature of Business (Detail Narr

Nature of Business (Detail Narrative)	Jan. 12, 2021USD ($)	Aug. 31, 2019USD ($)	Aug. 31, 2021USD ($)	Feb. 28, 2022USD ($)	Feb. 28, 2021USD ($)	Aug. 31, 2023USD ($)	Aug. 31, 2021USD ($)	Aug. 31, 2021CAD ($)	Aug. 31, 2020USD ($)	Aug. 31, 2020CAD ($)	Aug. 31, 2019USD ($)
Accumulated deficit			$ (31,829,204)	$ (35,248,137)			$ (31,829,204)
Repayment of loan				0	$ 23,163
Emergency Business Account Loan Program [Member]
Loss attributable to shareholders							$ 420,000		$ 4,100,000		$ 4,200,000
Accumulated deficit				(35,250,000)
Proceeds from underwritten public offering	$ 9,471,497
Proceeds from exercise of warrants			$ 4,015,043
Cash and cash equivalents				$ 8,400,000
Grant received for covid relief										$ 30,732
Repayment of loan								$ 30,000
Loan received from government										$ 40,000
Loan payable is anticipated to be forgiven		$ 10,000				$ 7,875

Basis of Consolidation (Detail

Basis of Consolidation (Detail Narrative)	Feb. 28, 2022
Lexaria Nicotine L L C [Member]
Equity interest percentage	83.333%
Altria Ventures Inc [Member]
Equity interest percentage	16.667%

Accounts and Other Receivable_2

Accounts and Other Receivables (Details) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Account receivable	$ 506,622	$ 342,401
Trade and deposits receivable [Member]
Account receivable	19,016	16,553
Sale of assets - shares receivable [Member]
Account receivable	278,107	287,107
Sales tax receivable [Member]
Account receivable	$ 209,499	$ 47,741

Inventory (Details)

Inventory (Details) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Inventory	$ 31,927	$ 29,648
Raw materials [Member]
Inventory	$ 31,927	$ 29,648

Inventory (Detail Narrative)

Inventory (Detail Narrative) - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Inventory
Finished goods write off	$ 0	$ 2,482

Intellectual Property (Details)

Intellectual Property (Details)	6 Months Ended
	Feb. 28, 2022
Patent one [Member]
Issued patent	US 9,474,725 B1
Patent certificate grant date Descriptions	10/25/2016
Patent Two [Member]
Issued patent	US 9,839,612 B2
Patent certificate grant date Descriptions	12/12/2017
Patent Three [Member]
Issued patent	US 9,972,680 B2
Patent certificate grant date Descriptions	05/15/2018
Patent Four [Member]
Issued patent	US 9,974,739 B2
Patent certificate grant date Descriptions	05/22/2018
Patent Five [Member]
Issued patent	US 10,084,044 B2
Patent certificate grant date Descriptions	09/25/2018
Patent Six [Member]
Issued patent	US 10,103,225 B2
Patent certificate grant date Descriptions	10/16/2018
Patent Seven [Member]
Issued patent	US 10,381,440
Patent certificate grant date Descriptions	08/13/2019
Patent Eight [Member]
Issued patent	US 10,374,036
Patent certificate grant date Descriptions	08/06/2019
Patent Nine [Member]
Issued patent	US 10,756,180
Patent certificate grant date Descriptions	08/25/2020

Intellectual Property (Details

Intellectual Property (Details 1) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2022	Aug. 31, 2020
Intellectual Property
Balance- beginning	$ 364,623	$ 292,000
Addition	50,263	79,493
Amortization	(3,434)	(6,870)
Balance - ending	$ 411,452	$ 364,623

Intellectual Property (Detail_2

Intellectual Property (Details Narrative)	6 Months Ended
	Feb. 28, 2022
Intellectual Property
Useful life of patents	20 years

Property Equipment (Details)

Property Equipment (Details) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2022	Aug. 31, 2021
Costs	$ 646,306	$ 649,400
Accumulated amortization	(329,870)	(279,093)
Additions	42,375
Disposal		(3,094)
Balance - end of the period	358,811	368,213
Period Amortization [Member]
Accumulated amortization	(51,777)	(115,144)
Leasehold Improvements [Member]
Costs	259,981	259,981
Accumulated amortization	(167,667)	(140,648)
Disposal		0
Balance - end of the period	92,314	119,333
Leasehold Improvements [Member] | Period Amortization [Member]
Accumulated amortization	(27,019)	(54,038)
Computer [Member]
Costs	63,964	63,964
Accumulated amortization	(59,625)	(51,550)
Disposal		0
Balance - end of the period	4,339	12,414
Computer [Member] | Period Amortization [Member]
Accumulated amortization	(8,075)	(19,681)
Furniture Fixtures Equipment [Member]
Costs	31,126	34,220
Accumulated amortization	(19,629)	(16,420)
Disposal		(3,094)
Balance - end of the period	11,497	14,706
Furniture Fixtures Equipment [Member] | Period Amortization [Member]
Accumulated amortization	(3,209)	(6,417)
Lab Equipment [Member]
Costs	291,235	291,235
Accumulated amortization	(82,949)	(69,475)
Additions	42,375
Disposal		0
Balance - end of the period	250,661	221,760
Lab Equipment [Member] | Period Amortization [Member]
Accumulated amortization	$ (13,474)	$ (35,008)

Property Equipment (Detail Narr

Property Equipment (Detail Narrative) - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Inventory
Amortization cost	$ 1,118	$ 6,010

Accounts Payable and Accrued _3

Accounts Payable and Accrued Liabilities (Details) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Accounts payable and accrued liabilities	$ 116,591	$ 100,723
Accrued Liabilities [Member]
Trades payable	22,474	45,000
Corporate tax payable	0	1,055
Accounts Payable [Member]
Trades payable	60,873	54,668
Sales tax payable	$ 33,244	$ 0

Common Shares and Warrants (Det

Common Shares and Warrants (Details) - $ / shares	6 Months Ended	12 Months Ended
	Feb. 28, 2022	Aug. 31, 2021
Common Shares and Warrants
Number of Warrants, Balance	2,447,275	471,608
Number of Warrants, Cancelled/Expired	(25,292)	(44,161)
Numbers of warrats exercised		(610,189)
Numbers of warrats issued		2,630,017
Number of Warrants, Balance	2,421,983	2,447,275
Weighted Average Exercise Price, Balance	$ 8	$ 16.77
Weighted Average Exercise Price, Cancelled/Expired	4.57	67.50
Weighted Average Exercise Price, Exercised		6.58
Weighted Average Exercise Price, Issued		6.58
Weighted Average Exercise Price, Balance	$ 8.04	$ 8

Common Shares and Warrants (D_2

Common Shares and Warrants (Details 1) - $ / shares	6 Months Ended
	Feb. 28, 2022	Nov. 30, 2021	Aug. 31, 2021	May 31, 2021	Aug. 31, 2020	Aug. 31, 2019	Aug. 31, 2018
Number of Warrants	2,421,983	2,421,983	2,447,275	3,057,464	471,608	94,177	3,286,274
Warrants 1
Number of Warrants	7,500
Weighted Average Remaining Contractual Life	8 months 4 days
Weighted Average Exercise Price	$ 24
Warrants 2
Number of Warrants	100,000
Weighted Average Remaining Contractual Life	2 years 1 month 17 days
Weighted Average Exercise Price	$ 9
Warrants 3
Number of Warrants	200,000
Weighted Average Remaining Contractual Life	2 years 1 month 17 days
Weighted Average Exercise Price	$ 7
Warrants 4
Number of Warrants	51,814
Weighted Average Remaining Contractual Life	2 years 8 months 15 days
Weighted Average Exercise Price	$ 36
Warrants 5
Number of Warrants	8,984
Weighted Average Remaining Contractual Life	2 years 9 months
Weighted Average Exercise Price	$ 36
Warrants 6
Number of Warrants	16,667
Weighted Average Remaining Contractual Life	3 years 18 days
Weighted Average Exercise Price	$ 9
Warrants 7
Number of Warrants	317,190
Weighted Average Remaining Contractual Life	3 years 2 months 12 days
Weighted Average Exercise Price	$ 10.50
Warrants 9
Number of Warrants	1,719,828
Weighted Average Remaining Contractual Life	3 years 10 months 17 days
Weighted Average Exercise Price	$ 6.58
Warrants 10
Number of Warrants	2,421,983
Weighted Average Remaining Contractual Life	3 years 6 months 10 days
Weighted Average Exercise Price	$ 8.04

Common Shares and Warrants (D_3

Common Shares and Warrants (Detail Narrative) - USD ($) $ in Millions	1 Months Ended	6 Months Ended
	Dec. 31, 2021	Feb. 28, 2022
Inventory
Warrant exercise, number of shares	224,299	0
Warrant exercise, value	$ 1.2

Stock Options (Details)

Stock Options (Details) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2022	Aug. 31, 2021
Stock Options
Balance, Outstanding	206,170	171,604
Expired/Cancelled	(3,334)	(50,334)
Granted	81,800	84,900
Balance, Outstanding	284,636	206,170
Balance Exercisable	260,386
Weighted average exercise price, Balance, Outstanding	$ 8.90	$ 11.17
Weighted average exercise price, Expired/Cancelled	9.60	10.76
Weighted average exercise price, Granted	6.23	5.41
Weighted average exercise price, Balance, Outstanding	8.12	$ 8.90
Weighted average exercise price, Balance, Exercisable	$ 8.35
Weighted Average Remaining Contractual Term, Outstanding (Years)	3 years 7 months 9 days
Weighted Average Remaining Contractual Term, Exercisable (Years)	3 years 7 months 2 days
Aggregate Intrinsic Value, Outstanding	$ 0
Aggregate Intrinsic Value, Exercisable	$ 0

Stock Options (Details 1)

Stock Options (Details 1)	6 Months Ended
	Feb. 28, 2022USD ($)$ / shares
Stock Options
Expected life	5 years
Estimated fair value per option | $ / shares	$ 5.10
Expected volatility | $	$ 119
Risk-free interest rate	0.85%
Dividend yield	0.00%

Stock Options (Detail Narrative

Stock Options (Detail Narrative)	6 Months Ended
	Feb. 28, 2022
Stock Options
Description of incentives plan	The Company has established the Equity Incentive Plan whereby the board of directors may, from time to time, grant stock options up to the equivalent of 10% of the number of common shares issued and outstanding to directors, officers, employees, and consultants

Revenues (Details)

Revenues (Details) - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Income from operations	$ 44,530	$ 487,662
Licensing Revenue [Member]
Income from operations	16,160	255,844
Other Revenue [Member]
Income from operations	10,858	100
B2B [Member]
Income from operations	$ 17,512	$ 231,718

Revenues (Details Narrative)

Revenues (Details Narrative)	6 Months Ended
	Feb. 28, 2022USD ($)
Estimates and Judgments
Product revenues	$ 17,500
licensing usage	$ 16,000

Related Party Transactions (Det

Related Party Transactions (Detail Narrative) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Related Party Transaction
Accrued liabilities	$ 6,884
Due to related party	$ 0	$ 5,223

Segment Information (Details)

Segment Information (Details) - USD ($)	3 Months Ended		6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021	Aug. 31, 2021
Total assets	$ 11,414,564		$ 11,414,564		$ 13,266,817
Cost of goods sold	(6,387)	$ (30,570)	(11,957)	$ (95,048)
Operating expense	(1,472,936)	(1,265,950)	(3,484,728)	(2,210,249)
Segment loss	(1,448,673)	(1,104,514)	(3,452,155)	(1,817,635)
B2B [Member]
Total assets	87,291	137,282	87,291	137,282
Revenue			17,512	231,818
Cost of goods sold			(11,957)	(95,048)
Operating expense			190,611	278,374
Segment loss			(185,056)	(141,604)
Consolidated Total [Member]
Total assets	11,414,564	12,172,408	11,414,564	12,172,408
Revenue			44,530	487,662
Cost of goods sold			(11,957)	(95,048)
Operating expense			3,484,729	687,545
Discontinued Operations				(22,000)
Segment loss			(3,452,156)	(316,931)
IP Licensing
Total assets	939,790	696,493	939,790	696,493
Revenue			16,160	255,844
Cost of goods sold			0	0
Operating expense			1,367,712	(1,142,518)
Discontinued Operations				(22,000)
Segment loss			(1,351,552)	1,376,362
Corporate [Member]
Total assets	$ 10,387,483	$ 11,338,633	10,387,483	11,338,633
Revenue			10,858	0
Cost of goods sold			0	0
Operating expense			1,926,406	1,551,689
Segment loss			$ (1,915,548)	$ (1,551,689)

Segment Information (Details 1)

Segment Information (Details 1) - USD ($)	6 Months Ended
	Feb. 28, 2022	Aug. 31, 2021
Net Balance	$ 358,811	$ 368,213
Addition	42,375
Leasehold Improvements [Member]
Net Balance	92,314	119,333
Furniture Fixtures Equipment [Member]
Net Balance	11,497	14,706
Lab Equipment [Member]
Net Balance	250,661	221,760
Addition	42,375
Computer Equipment [Member]
Net Balance	4,339	12,414
United States [Member]
Net Balance	108,144	69,580
Cost	98,050	101,144
Addition	42,375
Disposals		(3,094)
United States [Member] | Leasehold Improvements [Member]
Net Balance	0	0
Cost	0	0
Addition	0
Disposals		0
United States [Member] | Furniture Fixtures Equipment [Member]
Net Balance	0	0
Cost	0	3,094
Addition	0
Disposals		(3,094)
United States [Member] | Lab Equipment [Member]
Net Balance	108,144	69,580
Cost	98,050	98,050
Addition	42,375
Disposals		0
United States [Member] | Computer Equipment [Member]
Net Balance	0	0
Cost	0	0
Addition	0
Disposals		0
CANADA
Net Balance	250,667	298,633
Cost	548,256	548,256
CANADA | Leasehold Improvements [Member]
Net Balance	92,314	119,333
Cost	259,981	259,981
CANADA | Furniture Fixtures Equipment [Member]
Net Balance	11,497	14,706
Cost	31,126	31,126
CANADA | Lab Equipment [Member]
Net Balance	142,517	152,180
Cost	193,185	193,185
CANADA | Computer Equipment [Member]
Net Balance	4,339	12,414
Cost	$ 63,964	$ 63,964

Commitments Significant Contr_3

Commitments Significant Contracts and Contingencies (Details) - USD ($)	6 Months Ended		12 Months Ended
	Feb. 28, 2022	Feb. 28, 2021	Aug. 31, 2021
Commitments Significant Contracts and Contingencies
Right of use assets - operating leases:	$ 126,920		$ 126,920
Amortization expenses	(54,821)		(35,879)
Total lease assets	72,099		91,041
Liabilities operating lease	89,393		125,431
Lease payments	(22,191)	$ (21,975)	(43,950)
Interest accretion	2,954		7,912
Total lease liabilities	70,156		89,393
Operating lease cost	72,099		91,041
Operating cash flows for lease	$ 22,191		$ 43,950
Remaining lease term	1 year 8 months 12 days		2 years 1 month 6 days
Discount rate	7.50%		7.50%

Commitments Significant Contr_4

Commitments Significant Contracts and Contingencies (Details 1) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Commitments Significant Contracts and Contingencies
2022	$ 22,407
2023	44,816
2024	7,469
Thereafter	0
Total lease payments	74,692
Less: imputed interest	(4,536)
Present value of operating lease liabilities	70,156
Less: current obligations under leases	(41,076)	$ (39,404)
Total	$ 29,080	$ 49,989

Prepaid Expenses and Deposits (

Prepaid Expenses and Deposits (Details) - USD ($)	Feb. 28, 2022	Aug. 31, 2021
Prepaid Expenses and Deposits
Advertising and Conferences	$ 1,015,367	$ 168,760
Consulting	0	18,750
Legal fees	25,000	31,380
Licence, filing fees, dues	37,500	19,500
Office and insurance	44,094	80,863
Prepaid Expenses and Deposits	$ 1,121,961	$ 319,253

Marketable Securities (Details)

Marketable Securities (Details) - USD ($)	6 Months Ended	12 Months Ended
	Feb. 28, 2022	Aug. 31, 2021
Total [Member]
Cost Basis	$ 1,037,025	$ 1,037,025
Unrealized Gains	73,156	16,243
Unrealized Losses	(340,417)	(219,427)
Total	552,317	833,841
Common Stock [Member]
Cost Basis	0	1,037,025
Unrealized Gains	58,893	16,243
Unrealized Losses	(340,417)	$ (219,427)
Total	$ 281,524

Discontinued Operations (Detail

Discontinued Operations (Details)	6 Months Ended
	Feb. 28, 2022USD ($)
Gain on asset disposal
Book Value Of Assets Sold	$ 0
Cash consideration	273,373
Shares Received	468,264
Shares receivable	781,067
Promissory note	0
Gain on assets disposal	$ 1,522,704

Discontinued Operations (Deta_2

Discontinued Operations (Details 1) - USD ($)	3 Months Ended	6 Months Ended
	Feb. 28, 2021	Feb. 28, 2022	Feb. 28, 2021
Discontinued Operations
Revenues		$ 0	$ 3,000
Operating Expenses		0	(25,000)
Net income	$ 404,111	$ 0	$ (22,000)

Discontinued Operations (Deta_3

Discontinued Operations (Details 2) - USD ($)	6 Months Ended
	Feb. 28, 2022	Feb. 28, 2021
Cash flows used in discontinued operating activities
Net Income	$ 0	$ (22,000)
Change in working capital	0	105,000
Net cash used in discontinued operating activities	0	83,000
Net cash provided by discontinued operations	$ 0	$ 83,000

Discontinued Operations (Deta_4

Discontinued Operations (Detail Narrative)	Dec. 10, 2021CAD ($)shares	Dec. 10, 2021USD ($)shares	Nov. 19, 2020CAD ($)	Apr. 09, 2022USD ($)	Aug. 09, 2021USD ($)
Lexaria Canpharm Ulc [Member]
Gross proceeds from sale non-core business assets			$ 3,850,000
Hill Street Beverage Company Inc [Member]
Gross proceeds from sale non-core business assets		$ 350,000
Fair value	$ 500,000
Restricted common shares received from sale of assets, shares | shares	6,031,363	6,031,363
Promissory note received	$ 2,000,000
common Stock Issued					$ 1,000,000
Hill Street shares				$ 356,061	$ 643,939
Interest rate	10.00%	10.00%

Subsequent Events (Details Narr

Subsequent Events (Details Narrative) - Subsequent Event [Member]	Mar. 08, 2022$ / sharesshares
Stock option to be issued, shares | shares	36,700
Stock option price per share | $ / shares	$ 3.39